



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/664,817	09/17/2003	Barry Reisberg	1049-1-034N	3446
23565	7590	06/22/2005		
KLAUBER & JACKSON 411 HACKENSACK AVENUE HACKENSACK, NJ 07601			EXAMINER ROYDS, LESLIE A	
			ART UNIT	PAPER NUMBER
			1614	

DATE MAILED: 06/22/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

06172005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Please see attached.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/664,817	REISBERG, BARRY	
	Examiner	Art Unit	
	Leslie A. Royds	1614	

All Participants:

Status of Application: Pending

(1) Leslie A. Royds.

(3) _____

(2) Veronica Mallon.

(4) _____

Date of Interview: 17 June 2005

Time: AM

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

None.

Claims discussed:

None.

Prior art documents discussed:

None.


Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.


- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature — if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Ms. Mallon called to ask where "salicylates" would fall in the groups of second agents set forth in the written restriction requirement, since she could not locate it in the list of choices of group B. Examiner confirmed that the agent "salicylates" was inadvertently omitted from the subject matter of group XVIII. Examiner stated that should Applicant wish to choose "salicylates" as the second agent, then the choice of XVIII is appropriate. Ms. Mallon agreed and will contact Examiner with any further questions.



RAYMOND HENLEY III
PRIMARY EXAMINER
A61214